Showing 1551-1560 of 5771 results for "".
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Harrow Announces Permanent, Product-Specific J-Code for Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-permanent-product-specific-j-code-j2403-for-iheezo-for-ocular-surface-anesthesia/2481378/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Under the Healthcare Common Procedure Coding System (HCPCS), the Iheezo J‑co
- Bausch + Lomb and Modulight Announce FDA Approval of Photodynamic Laser for Use with Visudynehttps://modernod.com/news/bausch-lomb-and-modulight-announce-fda-approval-of-ml6710i-photodynamic-laser-for-use-with-bausch-lombs-visudyne/2481374/Bausch + Lomb and Modulight announced that the FDA has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s Visudyne (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choro
- Glaucoma Research Foundation to Recognize Santen Pharmaceutical at Annual Gala in San Franciscohttps://modernod.com/news/glaucoma-research-foundation-to-recognize-santen-pharmaceutical-at-annual-gala-in-san-francisco/2481369/Santen Pharmaceutical will receive the Glaucoma Research Foundation's Catalyst Award at the Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco, the foundation's President and CEO Thomas M. Brunner announced. Santen is being recognized for th
- Sight Sciences Announces 1,000th TearCare Customer Installationhttps://modernod.com/news/sight-sciences-announces-1000th-tearcare-customer-installation/2481366/Sight Sciences announced the 1,000th installation of its TearCare System. TearCare is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction wi
- Ocuphire Announces Phase 2 Topline Results of Oral Drug Candidate for Treatment of Diabetic Retinopathyhttps://modernod.com/news/ocuphire-announces-topline-results-from-zeta-1-phase-2-trial-of-oral-apx3330-in-diabetic-retinopathy/2481365/Ocuphire Pharma announced topline efficacy and safety results from its ZETA-1 phase 2 trial evaluating oral APX3330 for the treatment of diabetic retinopathy (DR). “Our goals in this initial retina phase 2 trial were to explore multiple endpoints to evaluate the potential for APX3
- OcuSciences Announces Publication of Study Showing Flavoprotein Fluorescence Measure Is Increased in Inherited Retinal Dystrophieshttps://modernod.com/news/ocusciences-announces-publication-of-study-showing-flavoprotein-fluorescence-measure-is-increased-in-inherited-retinal-dystrophies/2481358/OcuSciences announced the publication of a rare inherited mitochondrial diseases study in
- Horizon Therapeutics Announces Phase 2 Trial Results Evaluating Dazodalibep for the Treatment of Sjögren’s Syndromehttps://modernod.com/news/horizon-therapeutics-announces-phase-2-trial-results-evaluating-dazodalibep-for-the-treatment-of-sjogrens-syndrome/2481357/Horizon Therapeutics announced that the primary endpoint was met for the second population in its phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome. The phase 2 trial evaluated two patient populations and positive results in the first patient po
- Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defectshttps://modernod.com/news/trefoil-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-tthx1114-for-treatment-of-corneal-epithelial-defects/2481356/Trefoil Therapeutics announced dosing of the first patient in its phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects. The phase 1 study is designed to assess t
- Pixium Vision Announces Publications Demonstrating the Potential of the Next Generation PRIMA Implanthttps://modernod.com/news/pixium-vision-announces-publications-demonstrating-the-potential-of-the-next-generation-prima-implant/2481348/Pixium Vision announced that the second generation of implants for its bionic vision system PRIMA for atrophic age-related macular degeneration (AMD) could restore vision at five times higher resolution than the current PRIMA implants, according to a company news release. Pixi